5. Prevalence and duration of adrenal insufficiency evaluated by an ACTH stimulation test.
| Felner et al | Therapy: dexamethasone (cumulative dose 168 mg/m2) | |||
| Time after cessation | Before | 1 day | 4 weeks | 8 weeks |
| n insufficient/n total | 0/10 | 10/10 | 3/10 | 0/10 |
| Petersen et al (1) | Therapy: prednisolone (cumulative dose 2257.5 mg/m2)a | |||
| Time after cessation | 1 week | 3 weeks | 7 weeks | End of follow‐up: 10, 11, 11, and 19 weeks, respectively |
| n insufficient/n total | 7/10 | 6/10 | 4/10 | 4/10 |
| Petersen et al (2) | Therapy: dexamethasone (cumulative dose 236.25 mg/m2)b | |||
| Time after cessation | 1 week | 3 weeks | 7 weeks | End of follow‐up: 16, 33, and 34 weeks, respectively |
| n insufficient/n total | 5/7 | 4/7 | 3/7 | 3/7 |
ACTH: adrenocorticotropic hormone. a One child received additional 840 mg/m2 prednisolone during the period of adrenal insufficiency.
b These children received prednisolone 2257.5 mg/m2 as induction therapy before. Three high‐risk patients received an additional 560 mg/m2 prednisolone in advance. Furthermore, owing to persistent adrenal insufficiency, one of these high‐risk children received an additional 420 mg/m2 prednisolone during the period of insufficiency, and the other two high‐risk children received an additional 1260 mg/m2 prednisolone during that period.